Clinical trial
Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors
NCT00105170 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT00105170 |
|---|---|
| Title | Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors |
| Official title | A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of hCBE-11, a Humanized Monoclonal Antibody, in Subjects With Advanced Solid Tumors |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | hCBE-11 |
| Enrollment | 13 |
| Start date | Jan 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Mar 9, 2005 |
| Last update posted | Apr 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: